Truscreen GroupASX:TRU Net Margin % is -163.80% as of Mar. 2025. The stock has 6 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Truscreen Group ranks worse than 84.09% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Truscreen Group's Net Income for the
six
months ended in Mar. 2025 was A$-1.01 Mil. Truscreen Group's Revenue for the
six
months ended in Mar. 2025 was A$0.62 Mil. Therefore, Truscreen Group's net margin for the quarter that ended in Mar. 2025 was -163.80%.
The historical rank and industry rank for Truscreen Group's Net Margin % or its related term are showing as below:
ASX:TRU'
s Net Margin % Range Over the Past 10 Years
Min: -605.3 Med: -248.01 Max: -92.56
Current: -131.02
ASX:TRU's Net Margin % is ranked worse than 84.09% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs ASX:TRU: -131.02
Truscreen Group (ASX:TRU) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Truscreen Group Net Margin % Related Terms
Truscreen Group Net Margin % Historical Data
* Premium members only.
The historical data trend for Truscreen Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Truscreen Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Truscreen Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group (ASX:TRU) has a Net Margin % of -163.80% as of Mar. 2025. Net margin is the ratio of total net income to net sales. View historical data on Truscreen Group and its competitors. According to the industry distribution chart, Truscreen Group ranks #687 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 84.1%.
Is Truscreen Group's Net Margin % too high?
Truscreen Group's current Net Margin % is -163.80%. Based on the distribution chart, Truscreen Group ranks #687 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Truscreen Group's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Truscreen Group ranks #687 out of 817 companies for Net Margin %. This places Truscreen Group in the lower half of its industry. The industry median Net Margin % is 2.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Truscreen Group and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Truscreen Group's current Net Margin % is -163.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 40% above its estimated fair value. The current Net Margin % is -163.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current Net Margin % is -163.80% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRU has been successfully added to your 